Stories

Updates: Lilly's Global COVID-19 Response

View Story

Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization

View Story

When the World Called for Help with COVID-19, We Were Ready

View Story

Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody

View Story

An Update on Lilly’s Commitment to Quality Manufacturing

View Story

CEO Dave Ricks Shares Lilly's Principles of COVID-19 Antibody Therapy Pricing and Access

View Story

Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial

View Story

Lilly’s Commitment to Quality Manufacturing

View Story

Still image from CAR-approved video; employee consent is on file

Lilly Global Day of Service Goes Virtual and Remote to Improve Health, Education and Communities

View Story

Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial

View Story